334 related articles for article (PubMed ID: 19914319)
41. Nanotechnology approaches for delivery of cytochrome P450 substrates in HIV treatment.
Gong Y; Chowdhury P; Nagesh PKB; Cory TJ; Dezfuli C; Kodidela S; Singh A; Yallapu MM; Kumar S
Expert Opin Drug Deliv; 2019 Aug; 16(8):869-882. PubMed ID: 31328582
[No Abstract] [Full Text] [Related]
42. Insights on Oral Drug Delivery of Lipid Nanocarriers: a Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs.
Nabi B; Rehman S; Baboota S; Ali J
AAPS PharmSciTech; 2019 Jan; 20(2):60. PubMed ID: 30623263
[TBL] [Abstract][Full Text] [Related]
43. NanoART, neuroAIDS and CNS drug delivery.
Nowacek A; Gendelman HE
Nanomedicine (Lond); 2009 Jul; 4(5):557-74. PubMed ID: 19572821
[TBL] [Abstract][Full Text] [Related]
44. Preventing and managing antiretroviral drug resistance.
Kuritzkes DR
AIDS Patient Care STDS; 2004 May; 18(5):259-73. PubMed ID: 15186710
[TBL] [Abstract][Full Text] [Related]
45. Nanoparticle- and liposome-carried drugs: new strategies for active targeting and drug delivery across blood-brain barrier.
Pinzón-Daza ML; Campia I; Kopecka J; Garzón R; Ghigo D; Riganti C
Curr Drug Metab; 2013 Jul; 14(6):625-40. PubMed ID: 23869808
[TBL] [Abstract][Full Text] [Related]
46. Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters.
Strazielle N; Belin MF; Ghersi-Egea JF
AIDS; 2003 Jul; 17(10):1473-85. PubMed ID: 12824785
[TBL] [Abstract][Full Text] [Related]
47. Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS.
Nair M; Jayant RD; Kaushik A; Sagar V
Adv Drug Deliv Rev; 2016 Aug; 103():202-217. PubMed ID: 26944096
[TBL] [Abstract][Full Text] [Related]
48. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead.
Sosnik A; Chiappetta DA; Carcaboso AM
J Control Release; 2009 Aug; 138(1):2-15. PubMed ID: 19445981
[TBL] [Abstract][Full Text] [Related]
49. Polymeric nanoparticles for enhancing antiretroviral drug therapy.
Govender T; Ojewole E; Naidoo P; Mackraj I
Drug Deliv; 2008 Nov; 15(8):493-501. PubMed ID: 18720133
[TBL] [Abstract][Full Text] [Related]
50. Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV.
Ramana LN; Sharma S; Sethuraman S; Ranga U; Krishnan UM
Eur J Pharm Biopharm; 2015 Jan; 89():300-11. PubMed ID: 25500283
[TBL] [Abstract][Full Text] [Related]
51. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
[TBL] [Abstract][Full Text] [Related]
52. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites.
Vyas TK; Shah L; Amiji MM
Expert Opin Drug Deliv; 2006 Sep; 3(5):613-28. PubMed ID: 16948557
[TBL] [Abstract][Full Text] [Related]
53. Alzheimer's Disease and its Related Dementia Types: A Review on Their Management
Siafaka PI; Mutlu G; Okur NÜ
Curr Alzheimer Res; 2020; 17(14):1239-1261. PubMed ID: 33602090
[TBL] [Abstract][Full Text] [Related]
54. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):107-14. PubMed ID: 25402233
[TBL] [Abstract][Full Text] [Related]
55. Cerebral Vascular Toxicity of Antiretroviral Therapy.
Bertrand L; Velichkovska M; Toborek M
J Neuroimmune Pharmacol; 2021 Mar; 16(1):74-89. PubMed ID: 31209776
[TBL] [Abstract][Full Text] [Related]
56. Nano-enabled delivery systems across the blood-brain barrier.
Hwang SR; Kim K
Arch Pharm Res; 2014 Jan; 37(1):24-30. PubMed ID: 24170511
[TBL] [Abstract][Full Text] [Related]
57. Nano-based drug delivery system: a smart alternative towards eradication of viral sanctuaries in management of NeuroAIDS.
Aggarwal N; Sachin ; Nabi B; Aggarwal S; Baboota S; Ali J
Drug Deliv Transl Res; 2022 Jan; 12(1):27-48. PubMed ID: 33486689
[TBL] [Abstract][Full Text] [Related]
58. Nanostructure-based drug delivery systems for brain targeting.
Haque S; Md S; Alam MI; Sahni JK; Ali J; Baboota S
Drug Dev Ind Pharm; 2012 Apr; 38(4):387-411. PubMed ID: 21954902
[TBL] [Abstract][Full Text] [Related]
59. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
60. Dysfunction of ABC Transporters at the Surface of BBB: Potential Implications in Intractable Epilepsy and Applications of Nanotechnology Enabled Drug Delivery.
Mohi-Ud-Din R; Mir RH; Mir PA; Banday N; Shah AJ; Sawhney G; Bhat MM; Batiha GE; Pottoo FH
Curr Drug Metab; 2022; 23(9):735-756. PubMed ID: 35980054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
